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Case report
Chylomicronemia is a severe type of hypertriglyceridemia characterized by 
chylomicron accumulation that arises from a genetic defect in intravascular 
lipolysis. It requires urgent and proper management, because serious cases can 
be accompanied by pancreatic necrosis or persistent multiple organ failure. 
We present the case of a 1-month-old infant with chylomicronemia treated by 
plasmapheresis. His chylomicronemia was discovered incidentally when lactescent 
plasma was noticed during routine blood sampling during a hospital admission 
for fever and irritability. Laboratory investigation revealed marked triglyceri-
demia (>5,000 mg/dL) with high chylomicron levels. We therefore decided to 
perform a therapeutic plasmapheresis to prevent acute pancreatitis. Sequence 
analysis revealed a homozygous novel mutation in exon 4 of GPIHBP1: c.476delG 
(p.Gly159Alafs). Glycosylphosphatidylinositol-anchored high density lipoprotein-
binding protein 1 (GPIHBP1) stabilizes the binding of chylomicrons near lipoprotein 
lipase and supports lipolysis. Mutations of GPIHBP1, the most recently discovered 
gene, can lead to severe hyperlipidemia and are known to make up only 2% 
of the monogenic mutations associated with chylomicronemia. The patient 
maintains mild hypertriglyceridemia without rebound after single plasmapheresis 
and maintenance fibrate medication so far. Here, we report an infant with 
chylomicronemia due to GPIHBP1 mutation, successfully treated by plasmapheresis. 
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Severe hypertriglyceridemia is diagnosed when the plasma triglyceride (TG) concentration 
exceeds 885 mg/dL1). Chylomicronemia, formerly known as type 1 hyperlipoproteinemia, is 
a type of severe hypertriglyceridemia characterized by the accumulation of chylomicrons in 
fasting plasma2). 
Chylomicronemia usually presents in infancy or childhood with episodes of eruptive 
xanthomas on the trunk and extremities, lipaemia retinalis, recurrent abdominal pain, acute 
and/or chronic pancreatitis and hepatosplenomegaly3). It is often discovered incidentally 
by lactescent plasma during routine blood sampling. The most serious manifestation is 
pancreatitis, which is associated with 5%–6% overall mortality, and the highest mortality rate is 
related to the development of pancreatic necrosis or persistent multiple organ failure4). 
Familial chylomicronemia has a monogenic basis with autosomal recessive pattern and 
arises from inactivating mutations in genes that encode key check-point molecules in lipolysis 
such as lipoprotein lipase (LPL), apolipoprotein C2 (APOC2), apolipoprotein A5 (APOA5), 
lipase maturation factor 1 (LMF1), or glycosylphosphatidylinositol-anchored high density 
lipoprotein-binding protein 1 (GPIHBP1)5,6). 
GPIHBP1 binds LPL and translocates the enzyme to the luminal surface of capillary 
endothelial cells, thus supporting lipolysis7). GPIHBP1 mutations may disturb lipolytic 
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processing, which leads to severe hypertriglyceridemia, and to 
date this disturbance has been reported in only 26 families8-11).
The mainstay of treatment is a restriction of fat intake to less 
than or equal to 15% of total energy intake, and especially infants 
are given medium chain triglycerides (MCTs) milk, which are 
not incorporated into chylomicrons12). However, in cases with 
very high TG levels, dietary treatment may be insufficient for 
preventing pancreatitis, and nonpharmacological treatment, 
such as plasma exchange, becomes necessary. 
 Here, we report a 1-month-old infant with chylomicronemia 
due to a GPIHBP1 mutation and how he was treated by extra-
corporeal methods.
Case report 
A 40-day-old male infant, born at 39 weeks and 3.3 kg 
by caesarean section without perinatal complications, was 
hospitalized with fever and irritability for 1 day. His height 
was 56 cm (25th–50th percentile) and weight was 4.6 kg 
(5th–10th percentile) with absolute breastfeeding. When a 
blood sample was taken for evaluation, physicians noticed 
lactescent plasma. He was then referred to the pediatric 
endocrinology clinic. He was the only child, and his family 
history was unremarkable. Physical examination did not 
reveal specific findings for dyslipidemia such as xanthomas 
and hepatosplenomegaly. His vital signs were stable with mild 
fever and mild tachycardia (blood pressure, 85/45 mmHg; 
heart rate, 140 beats/min; respiratory rate, 35 breaths/min; 
body temperature, 37.8℃). Laboratory investigation revealed 
pronounced hypertriglyceridemia (>5,000 mg/dL; normal 
range, 50 to 150 mg/dL), and hypercholesterolemia with total 
cholesterol at 988 mg/dL (normal range, 120 to 200 mg/dL), 
high-density lipoprotein cholesterol at 390 mg/dL (normal 
range, 40 to 75 mg/dL), and low-density lipoprotein cholesterol 
at 9 mg/dL (normal range, 70 to 160 mg/dL). Amylase and lipase 
levels were normal. Serum albumin was slightly lower than 
normal (3.2 g/dL; normal range, 3.8 to 5.4 g/dL), but there was 
no proteinuria or clinical symptom. The analysis of lipoproteins 
showed high chylomicron at 24.0% (normal range, 0–0.4), low 
alpha lipoprotein at 0.4% (normal range, 15.6–39.1), and low 
beta lipoprotein at 18.5% (normal range, 37.2–64.0). Primary 
chylomicronemia was diagnosed on this basis.
The first therapeutic measure was to give a diet free of 
long chain fatty acids by means of MCTs milk. In addition, 
therapeutic plasmapheresis was necessary to manage the high 
risk of pancreatitis. Therapeutic plasma exchange (Spectra optia, 
Thermo BCT Inc., Lakewood, CO, USA) was carried out using 
fresh frozen plasma and 20% albumin. Body weight was 4.6 
kg and the patient's estimated blood volume was 345 mL. The 
blood flow rate was 6 mL/min and total procedure time was 150 
minutes (removed volume, 373 mL; replaced volume, 318 mL) 
(Table 1). Anticoagulation was also performed by heparin bolus 
(30 IU/kg). During the procedure, vital signs, bleeding tendency, 
and electrolytes were carefully monitored, and there were no 
significant side effects such as hypovolemic shock. The patient 
tolerated the procedure, and blood samples were collected 
before and 24, 48, and 72 hours after the procedure to assess the 
TG rebound. Immediately after plasmapheresis, the TG level 
had dropped to 2,125 mg/dL and then gradually decreased to 
1,230 mg/dL, 465 mg/dL, and 444 mg/dL after 24 hours, 48 
hours, and 72 hours, respectively (Fig. 1). In addition, we started 
fibrate medication (Bezalip 30 mg/kg per day) and MCT oil. 
The patient was discharged 6 days after admission, and he 
continues to be regularly followed-up in the outpatient clinic to 
monitor his lipid profiles. For now, he is 1 year old with normal 
growth parameters; his height is 77 cm (25th–50th percentile) 
and weight is 10.2 kg (25th–50th percentile). The TG level 
stayed below 700 mg/dL during 1 year with same fibrate dosage 
without complications.
To identify the cause of chylomicronemia, genetic direct 
sequencing was performed. During the genetic investigation, 
a novel homozygous mutation was revealed in exon 4 of 
GPIHBP1 (c.476delG, p.Gly159Alafs), the gene that stabilizes 
the binding of chylomicrons near LPL and supports lipolysis 
(Fig. 2). Furthermore, genetic sequencing was performed for 
both parents, and his father harbored a heterozygous mutation, 
whereas, his mother had no mutation in GPIHBP1.
Discussion
In this study, we have described a 1-month-old infant who 
Fig. 1. Plasma triglyceride and cholesterol levels before and after plasma 
exchange.
Table 1. Plasma exchange technical parameters in 1-month-old 
infant with chylomicronemia
Technical parameters for 
  therapeutic plasma exchange Value
Patient’s body weight (kg) 4.6 
Anticoagulation (IU/kg) Heparin bolus, 30 
Blood flow rate (mL/min) 6 
Estimated blood volume (mL) 345
Removed volume (mL)
  Output 373 
  Input 318
Total processing time (min) 150
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was incidentally found to have chylomicronemia resulting 
from a GPIHBP1 mutation and treated by plasma exchange. 
Patients with TG levels greater than 885 mg/dL should be 
investigated by a step-wise approach. Secondary causes such as 
uncontrolled diabetes, hypothyroidism, poor diet, alcohol use, 
nephrotic syndrome, obesity, and a variety of medications can 
be responsible for severe hypertriglyceridemia in children13). 
If there is no secondary cause, monogenic factors should be 
considered. LPL deficiency is the most common cause of 
monogenic chylomicronemia. In the past, biochemical studies 
have been used to determine LPL or APOC2 activities, but 
nowadays genetic sequencing is performed for diagnosis. 
Patients with monogenic chylomicronemia show homozygosity 
or compound heterozygosity for loss-of-function mutations 
in causative genes such as LPL, APOC2, APOA5, LMF1, 
and GPIHBP114). Mutations in GPIHBP1, the most recently 
discovered gene, make up only 2% of monogenic mutations2). In 
the case at hand, the patient had a homozygous GPIHBP1 muta-
tion and his father had a heterozygous mutation. Therefore, 
we can suppose that one allele was inherited from his father, 
and the other was from de novo mutation. Also, there was 
a possibility of paternal uniparental disomy as well. To our 
knowledge, only a few cases of infant monogenic chylomicro-
nemia due to GPIHBP1 mutations have been reported. One 
was a 2-month-old infant homozygous for GPIHBP1 deletions 
who was treated with a low-fat formula diet8). The other was a 
6-month-old infant with novel biallelic mutations in GPIHBP1 
who improved on MCT-rich formula15). The case at hand is 
therefore the youngest case with GPIHBP1 mutations who has 
been treated by plasmapheresis reported so far.
The mainstay of chylomicronemia therapy is an extremely 
low-fat diet, and especially in infants supplemental MCTs 
provide additional calories without raising circulating TG levels. 
However, the long-term effects of diets with high levels of MCTs 
remain unknown15). In addition, traditional lipid-lowering 
medications, such as fibrates, niacin and statins, are minimally 
effective in patients with primary chylomicronemia, especially 
patients with complete loss-of-function mutations in the 
lipolytic pathway2). Although there are few studies about efficacy 
and safety of fibrates in children with hypercholesterolemia, 
Becker et al.16) reported fibrate is an alternative, safe and effective 
therapeutic choice for treatment of severe familial hypercho-
lesterolemia in children. Therefore, we prescribed fibrate 
medication (Bezalip, 30 mg/kg per day) to reduce TG level 
definitely after single plasmapheresis.
Plasmapheresis or plasma exchange with direct removal 
of TG has been used, and plasma exchange is mentioned in 
the category III of the American Society for Apheresis 2010 
guidelines (recommendation grade 2C, type of evidence II-I) 
for the treatment of hypertriglyceridemia17). In infant patients, 
Stefanutti et al.18) have reported successful plasmapheresis in 
a 25-day-old, 3.9-kg male with chylomicronemia whose TG 
level reached 38,000 mg/dL. Also Stefanutti et al.19) reported 
a 3-month-old infant with chylomicronemia treated with 
plasma exchange to avoid acute pancreatitis, whose TG level 
dropped dramatically within 72 hours (Initial TG level was 
167.00 mmol/L, 11.68 mmol/L after 72 hours after plasma 
exchange). In comparison with conservative management of 
chylomicronemia in a 2-month infant reported by Rios et al.8) 
(Initial TG level was >25,000 mg/dL, 397 mg/dL after 12 days), 
the use of plasma exchange showed effective removal of TG 
level. However, small clinical trials comparing plasmapheresis 
with conservative management have shown that plasmapheresis 
has no overall benefit4). In addition, the TG concentration may 
return to the preapheresis values after plasmapheresis and there 
are no precise guidelines for therapeutic plasmapheresis in 
chylomicronemia. In our case, the TG level was severely raised, 
to above 5,000 mg/dL, and we opted for a drastic management 
strategy, therapeutic plasmapheresis, to prevent the acute 
pancreatitis. Fortunately, this reduced the TG level dramatically 
without complications, to below 400 mg/dL, and it stayed below 
700 mg/dL for 1 year after only single plasmapheresis. Therefore, 
plasmapheresis may be an effective management strategy in 
infant patients with chylomicronemia, even though this is an 
invasive and risky procedure. 
Recently, a new therapeutic approach has emerged with 
lomitapide (microsomal triglyceride transfer protein inhibitor). 
This drug is currently approved in North America and Europe 
for the treatment of homozygous familial hypercholesterolemia 
and has been shown to reduce triglyceride levels by 30%–40%20). 
However, lomitapide is only recommended for patients with 
pancreatitis associated with severe hypertriglyceridemia and 
without active hepatitis20). In addition, the safety of this drug 
for infant patients has not been proven. Further clinical trials in 
younger children are needed.
In conclusion, we report the youngest case of chylomicro-
nemia due to GPIHBP1 mutation that has been successfully 
treated by plasmapheresis. Accordingly, this approach may be 
effective in infant patients with severe chylomicronemia.
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Fig. 2. The mutation of nucleotide sequence in GPIHBP1 gene in patient.
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